IndUced Pluripotent Stem Cells Model Personalized Variations in Liver Disease Resulting From α1-Antitrypsin Deficiency

Edgar N. Tafaleng, Souvik Chakraborty, Bing Han, Pamela Hale, Wanquan Wu, Alejandro Soto-Gutierrez, Carol A. Feghali-Bostwick, Andrew A. Wilson, Darrell N. Kotton, Masaki Nagaya, Stephen C. Strom, Jayanta Roy-Chowdhury, Donna B. Stolz, David H. Perlmutter, Ira J. Fox

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

In the classical form of α1-antitrypsin deficiency (ATD), aberrant intracellular accumulation of misfolded mutant α1-antitrypsin Z (ATZ) in hepatocytes causes hepatic damage by a gain-of-function, "proteotoxic" mechanism. Whereas some ATD patients develop severe liver disease (SLD) that necessitates liver transplantation, others with the same genetic defect completely escape this clinical phenotype. We investigated whether induced pluripotent stem cells (iPSCs) from ATD individuals with or without SLD could model these personalized variations in hepatic disease phenotypes. Patient-specific iPSCs were generated from ATD patients and a control and differentiated into hepatocyte-like cells (iHeps) having many characteristics of hepatocytes. Pulse-chase and endoglycosidase H analysis demonstrate that the iHeps recapitulate the abnormal accumulation and processing of the ATZ molecule, compared to the wild-type AT molecule. Measurements of the fate of intracellular ATZ show a marked delay in the rate of ATZ degradation in iHeps from SLD patients, compared to those from no liver disease patients. Transmission electron microscopy showed dilated rough endoplasmic reticulum in iHeps from all individuals with ATD, not in controls, but globular inclusions that are partially covered with ribosomes were observed only in iHeps from individuals with SLD. Conclusion: iHeps model the individual disease phenotypes of ATD patients with more rapid degradation of misfolded ATZ and lack of globular inclusions in cells from patients who have escaped liver disease. The results support the concept that "proteostasis" mechanisms, such as intracellular degradation pathways, play a role in observed variations in clinical phenotype and show that iPSCs can potentially be used to facilitate predictions of disease susceptibility for more precise and timely application of therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)147-157
Number of pages11
JournalHepatology
Volume62
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Induced Pluripotent Stem Cells
Liver Diseases
Hepatocytes
Phenotype
Rough Endoplasmic Reticulum
Glycoside Hydrolases
Liver
Disease Susceptibility
Transmission Electron Microscopy
Ribosomes
Liver Transplantation

ASJC Scopus subject areas

  • Hepatology

Cite this

Tafaleng, E. N., Chakraborty, S., Han, B., Hale, P., Wu, W., Soto-Gutierrez, A., ... Fox, I. J. (2015). IndUced Pluripotent Stem Cells Model Personalized Variations in Liver Disease Resulting From α1-Antitrypsin Deficiency. Hepatology, 62(1), 147-157. https://doi.org/10.1002/hep.27753

IndUced Pluripotent Stem Cells Model Personalized Variations in Liver Disease Resulting From α1-Antitrypsin Deficiency. / Tafaleng, Edgar N.; Chakraborty, Souvik; Han, Bing; Hale, Pamela; Wu, Wanquan; Soto-Gutierrez, Alejandro; Feghali-Bostwick, Carol A.; Wilson, Andrew A.; Kotton, Darrell N.; Nagaya, Masaki; Strom, Stephen C.; Roy-Chowdhury, Jayanta; Stolz, Donna B.; Perlmutter, David H.; Fox, Ira J.

In: Hepatology, Vol. 62, No. 1, 01.07.2015, p. 147-157.

Research output: Contribution to journalArticle

Tafaleng, EN, Chakraborty, S, Han, B, Hale, P, Wu, W, Soto-Gutierrez, A, Feghali-Bostwick, CA, Wilson, AA, Kotton, DN, Nagaya, M, Strom, SC, Roy-Chowdhury, J, Stolz, DB, Perlmutter, DH & Fox, IJ 2015, 'IndUced Pluripotent Stem Cells Model Personalized Variations in Liver Disease Resulting From α1-Antitrypsin Deficiency', Hepatology, vol. 62, no. 1, pp. 147-157. https://doi.org/10.1002/hep.27753
Tafaleng, Edgar N. ; Chakraborty, Souvik ; Han, Bing ; Hale, Pamela ; Wu, Wanquan ; Soto-Gutierrez, Alejandro ; Feghali-Bostwick, Carol A. ; Wilson, Andrew A. ; Kotton, Darrell N. ; Nagaya, Masaki ; Strom, Stephen C. ; Roy-Chowdhury, Jayanta ; Stolz, Donna B. ; Perlmutter, David H. ; Fox, Ira J. / IndUced Pluripotent Stem Cells Model Personalized Variations in Liver Disease Resulting From α1-Antitrypsin Deficiency. In: Hepatology. 2015 ; Vol. 62, No. 1. pp. 147-157.
@article{a93b719a55d145ffb3530d51ce472da6,
title = "IndUced Pluripotent Stem Cells Model Personalized Variations in Liver Disease Resulting From α1-Antitrypsin Deficiency",
abstract = "In the classical form of α1-antitrypsin deficiency (ATD), aberrant intracellular accumulation of misfolded mutant α1-antitrypsin Z (ATZ) in hepatocytes causes hepatic damage by a gain-of-function, {"}proteotoxic{"} mechanism. Whereas some ATD patients develop severe liver disease (SLD) that necessitates liver transplantation, others with the same genetic defect completely escape this clinical phenotype. We investigated whether induced pluripotent stem cells (iPSCs) from ATD individuals with or without SLD could model these personalized variations in hepatic disease phenotypes. Patient-specific iPSCs were generated from ATD patients and a control and differentiated into hepatocyte-like cells (iHeps) having many characteristics of hepatocytes. Pulse-chase and endoglycosidase H analysis demonstrate that the iHeps recapitulate the abnormal accumulation and processing of the ATZ molecule, compared to the wild-type AT molecule. Measurements of the fate of intracellular ATZ show a marked delay in the rate of ATZ degradation in iHeps from SLD patients, compared to those from no liver disease patients. Transmission electron microscopy showed dilated rough endoplasmic reticulum in iHeps from all individuals with ATD, not in controls, but globular inclusions that are partially covered with ribosomes were observed only in iHeps from individuals with SLD. Conclusion: iHeps model the individual disease phenotypes of ATD patients with more rapid degradation of misfolded ATZ and lack of globular inclusions in cells from patients who have escaped liver disease. The results support the concept that {"}proteostasis{"} mechanisms, such as intracellular degradation pathways, play a role in observed variations in clinical phenotype and show that iPSCs can potentially be used to facilitate predictions of disease susceptibility for more precise and timely application of therapeutic strategies.",
author = "Tafaleng, {Edgar N.} and Souvik Chakraborty and Bing Han and Pamela Hale and Wanquan Wu and Alejandro Soto-Gutierrez and Feghali-Bostwick, {Carol A.} and Wilson, {Andrew A.} and Kotton, {Darrell N.} and Masaki Nagaya and Strom, {Stephen C.} and Jayanta Roy-Chowdhury and Stolz, {Donna B.} and Perlmutter, {David H.} and Fox, {Ira J.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1002/hep.27753",
language = "English (US)",
volume = "62",
pages = "147--157",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - IndUced Pluripotent Stem Cells Model Personalized Variations in Liver Disease Resulting From α1-Antitrypsin Deficiency

AU - Tafaleng, Edgar N.

AU - Chakraborty, Souvik

AU - Han, Bing

AU - Hale, Pamela

AU - Wu, Wanquan

AU - Soto-Gutierrez, Alejandro

AU - Feghali-Bostwick, Carol A.

AU - Wilson, Andrew A.

AU - Kotton, Darrell N.

AU - Nagaya, Masaki

AU - Strom, Stephen C.

AU - Roy-Chowdhury, Jayanta

AU - Stolz, Donna B.

AU - Perlmutter, David H.

AU - Fox, Ira J.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - In the classical form of α1-antitrypsin deficiency (ATD), aberrant intracellular accumulation of misfolded mutant α1-antitrypsin Z (ATZ) in hepatocytes causes hepatic damage by a gain-of-function, "proteotoxic" mechanism. Whereas some ATD patients develop severe liver disease (SLD) that necessitates liver transplantation, others with the same genetic defect completely escape this clinical phenotype. We investigated whether induced pluripotent stem cells (iPSCs) from ATD individuals with or without SLD could model these personalized variations in hepatic disease phenotypes. Patient-specific iPSCs were generated from ATD patients and a control and differentiated into hepatocyte-like cells (iHeps) having many characteristics of hepatocytes. Pulse-chase and endoglycosidase H analysis demonstrate that the iHeps recapitulate the abnormal accumulation and processing of the ATZ molecule, compared to the wild-type AT molecule. Measurements of the fate of intracellular ATZ show a marked delay in the rate of ATZ degradation in iHeps from SLD patients, compared to those from no liver disease patients. Transmission electron microscopy showed dilated rough endoplasmic reticulum in iHeps from all individuals with ATD, not in controls, but globular inclusions that are partially covered with ribosomes were observed only in iHeps from individuals with SLD. Conclusion: iHeps model the individual disease phenotypes of ATD patients with more rapid degradation of misfolded ATZ and lack of globular inclusions in cells from patients who have escaped liver disease. The results support the concept that "proteostasis" mechanisms, such as intracellular degradation pathways, play a role in observed variations in clinical phenotype and show that iPSCs can potentially be used to facilitate predictions of disease susceptibility for more precise and timely application of therapeutic strategies.

AB - In the classical form of α1-antitrypsin deficiency (ATD), aberrant intracellular accumulation of misfolded mutant α1-antitrypsin Z (ATZ) in hepatocytes causes hepatic damage by a gain-of-function, "proteotoxic" mechanism. Whereas some ATD patients develop severe liver disease (SLD) that necessitates liver transplantation, others with the same genetic defect completely escape this clinical phenotype. We investigated whether induced pluripotent stem cells (iPSCs) from ATD individuals with or without SLD could model these personalized variations in hepatic disease phenotypes. Patient-specific iPSCs were generated from ATD patients and a control and differentiated into hepatocyte-like cells (iHeps) having many characteristics of hepatocytes. Pulse-chase and endoglycosidase H analysis demonstrate that the iHeps recapitulate the abnormal accumulation and processing of the ATZ molecule, compared to the wild-type AT molecule. Measurements of the fate of intracellular ATZ show a marked delay in the rate of ATZ degradation in iHeps from SLD patients, compared to those from no liver disease patients. Transmission electron microscopy showed dilated rough endoplasmic reticulum in iHeps from all individuals with ATD, not in controls, but globular inclusions that are partially covered with ribosomes were observed only in iHeps from individuals with SLD. Conclusion: iHeps model the individual disease phenotypes of ATD patients with more rapid degradation of misfolded ATZ and lack of globular inclusions in cells from patients who have escaped liver disease. The results support the concept that "proteostasis" mechanisms, such as intracellular degradation pathways, play a role in observed variations in clinical phenotype and show that iPSCs can potentially be used to facilitate predictions of disease susceptibility for more precise and timely application of therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84933178811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933178811&partnerID=8YFLogxK

U2 - 10.1002/hep.27753

DO - 10.1002/hep.27753

M3 - Article

C2 - 25690322

AN - SCOPUS:84933178811

VL - 62

SP - 147

EP - 157

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -